Tolterodine extended release is well tolerated in older subjects

Tolterodine extended release is well tolerated in older subjects

OBJECTIVES To investigate the tolerability of tolterodine extended release (ER) in older subjects with overactive bladder (OAB). METHODS This was a retrospective analysis of pooled data from five large, randomised, double-blind, placebo-controlled trials. Subjects with OAB symptoms, including urinary frequency and urgency (and nocturia in two studies) with or without urgency urinary incontine...

Use of Tolterodine extended Release in Overactive Bladder

Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises ­health-related­quality­of­life.­Tolterodine­was­the­first­antimuscarinic­drug­specifically­designed­to­treat­OAB. Through­MEDLINE,­we­reviewed­articles,­standardization­reports­and­meeting­abstracts,­published­between­2001­and­2011,­on­the­efficacy and tolerability of Tolterodine extended...

Update on tolterodine extended-release for treatment of overactive bladder

Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review prov...

Oxybutynin extended release and tolterodine immediate release : a health economic comparison.

OBJECTIVE To evaluate the cost-effectiveness of a new extended-release (XL) formulation of oxybutynin relative to tolterodine immediate release (IR), currently the most prescribed treatment for overactive bladder in the UK. METHODS A state-transition model was developed to compare outcomes over 1 year. Effectiveness and treatment persistence data were derived from the OBJECT (Overactive Bladd...

Patient tolerated procedure well.